Scientists have created a novel microbiome-based diagnostic tool that, with the accuracy of the best physicians, quickly and inexpensively identifies liver fibrosis and cirrhosis over 90 percent of the time in human patients. The non-invasive method relies on an algorithm to analyze patient stool samples — which contains traces of what lives in the gut — and could lead to improved patient care and treatment outcomes for liver disease.